Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PepsiCo : bets on vaccine-led reopenings for soda sales boost

04/15/2021 | 11:13pm EDT
FILE PHOTO: Cases of Pepsi are shown for sale at a store in Carlsbad

(Reuters) - PepsiCo Inc on Thursday predicted an acceleration in organic revenue growth in the second quarter, betting on a boost to soda sales from the gradual reopening of restaurants and theaters following the speedy rollout of coronavirus vaccines.

The company, a pandemic winner, has been benefiting from homebound consumers stocking up their pantries with salty chips, sodas and oatmeal, and posted first-quarter revenue that beat Wall Street expectations.

But with COVID-19 restrictions starting to ease, Pepsi expects its North American beverage business, a unit that aggressively competes with Coca-Cola for market share, to "perform well" and the snack unit to "remain resilient."

"We had been losing market share in the beverage space in the past... It's getting better. We are gaining share right now," Chief Financial Officer Hugh Johnston told Reuters.

Like other soda makers, PepsiCo lost some sales due to the closure of public venues due to the pandemic, but was able to cut back some losses as consumers bought drinks like bubly and Mountain Dew for their caffeine fix.

Pepsi has also been adding new energy drinks for health-conscious consumers who have adapted to a new active lifestyle and launched a hemp beverage in Europe.

Meanwhile, the company signaled uncertainty over demand for mutli-pack snacks as consumers start to return to offices and colleges.

"The consumer will show us more as we go along in the next, I would say, 6 to 9 months," Chief Executive Officer Ramon Laguarta told analysts.

Sales of snacks under its Frito-Lay North America unit rose 4% in the first quarter, while those of sodas and other beverages rose 5% in North America.

That helped net revenue gain 6.8% to $14.82 billion, beating market expectation of $14.55 billion, according to IBES data from Refinitiv.

On an adjusted basis, Pepsi earned $1.21 per share, well above the expectation of $1.12. (This story corrects typographical error in first paragraph)

(Reporting by Nivedita Balu in Bengaluru; Editing by Arun Koyyur)

By Nivedita Balu

© Reuters 2021
All news about PEPSICO, INC.
05/07PEPSICO INC  : Submission of Matters to a Vote of Security Holders (form 8-K)
05/06PEPSICO  : Appoints C.D. Glin as Vice President, Global Head of Philanthropy
05/05PEPSICO  : Raises Dividend to $1.075 Per Share; Payable June 30 to Shareholders ..
05/05PEPSICO  : Boosts Quarterly Dividend By 5%
05/04PEPSICO  : Declares Quarterly Dividend
05/04PEPSICO  : Announces Webcast of Annual Shareholders' Meeting
04/29PEPSICO  : Cheetos And Doritos Go Head-to-Head In Epic Flamin' Hot Faceoff
04/28PEPSICO  : Gatorade Creates A Women's Advisory Board
04/28PEPSICO  : Tostitos and Danny Trejo Give Fans 'Five Ways To Cinco' this Holiday
04/27PEPSICO  : Smartfood® Popcorn And Krispy Kreme® Unveil Iconic Flavor Mashup With..
More news
Financials (USD)
Sales 2021 75 415 M - -
Net income 2021 8 289 M - -
Net Debt 2021 34 589 M - -
P/E ratio 2021 24,2x
Yield 2021 2,91%
Capitalization 201 B 201 B -
EV / Sales 2021 3,13x
EV / Sales 2022 2,99x
Nbr of Employees 291 000
Free-Float 73,8%
Duration : Period :
PepsiCo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PEPSICO, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 154,09 $
Last Close Price 145,56 $
Spread / Highest target 13,4%
Spread / Average Target 5,86%
Spread / Lowest Target -7,25%
EPS Revisions
Managers and Directors
Ramon Luis Laguarta Chairman & Chief Executive Officer
Hugh F. Johnston Vice Chairman, Chief Financial Officer & EVP
Rene Lammers Chief Science Officer & Executive Vice President
Seth Cohen Chief Information Officer & Senior Vice President
Pietro Antonio Tataranni Chief Medical Officer & Senior VP-Life Sciences
Sector and Competitors